Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 99 EP458 | DOI: 10.1530/endoabs.99.EP458

1Hospital Clínico Valladolid, Endocrinology and Nutrition, Valladolid, Spain; 2University Clinical Hospital of Valladolid, Mental Health, Valladolid, Spain; 3University Clinical Hospital of Valladolid, Pediatrics, Valladolid, Spain


Introduction: Gender affirming hormone therapy (GAHT) in transgender men favors their virilization. Aims: To determine its impact on body composition measured by electrical impedance and the satisfaction perceived by the subject (CRES-4 questionnaire).

Material and Methods: Prospective study in transgender men with GAHT (>2 years), attended at the Transgender Medicine Unit of the Hospital Clinico of Valladolid from January 2014 to January 2023. Recording of clinical, analytical, body composition and CRES-4 questionnaire data after giving their consent. Statistical analysis of the data by the SPSS-V17 program.

Results: 32 transgender males aged 23 [22-32] years and onset of GAHT at 18 [17-25] years with long-acting testosterone ester 2 (6.3%), short-acting 26 (81.3%) and testosterone gel 4 (12.5%). The initial BMI was 21.9 [19.6-24.7] kg/m2, fat-free mass (FFM) 43.9 [40.8-47.4] kg, fat mass (FM) 15.6 [10.6-22.9] kg and estimated muscle mass (EMM) 29 [24.7-31.9] kg. At 2 years with testosterone, there was 0.82 [0.1-1.9] kg/m2 increase in BMI, 3.4[2-5] kg in FFM and 3.8 [1.7-8.1] kg in EMM. FM decreased -1.7[-3.3 to 1] kg. 21/22 subjects were satisfied with GAHT, with 255 [242-265] points on CRES-4. Serum testosterone (near the end of the dose interval) was 391 [264-817] ng/dl with 17 (53%) in the low range (</=400 ng/dl) and 15 (47%) subjects in the mid-high range of normal (>400 ng/dl). In both groups, changes in BMI (P=0.723), in FFM (P=0.288) and in FM (P=0.288) were similar. However, the increase in EMM was 4.9[2.8-10] kg in the low range and 3.3[1.2-7.1] kg in the mid-high range (P=0.077). CRES-4 score in the low range was 262 [250-275] and in the mid- high range 255 [242-262] points (p 0.273).

Conclusion: GAHT-induced body composition changes in transgender males were satisfactory. Even with testosterone levels near the end of the dosing interval in the low normal range.

Volume 99

26th European Congress of Endocrinology

Stockholm, Sweden
11 May 2024 - 14 May 2024

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.